Report cover image

Global Cancer Drugs Industry Growth and Trends Forecast to 2031

Publisher APO Research, Inc.
Published Oct 20, 2025
Length 128 Pages
SKU # APRC20548299

Description

Summary

According to APO Research, The global Cancer Drugs market was estimated at US$ million in 2025 and is projected to reach a revised size of US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2026-2031.

North American market for Cancer Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.

Asia-Pacific market for Cancer Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.

Europe market for Cancer Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.

The major global manufacturers of Cancer Drugs include Takeda, Eisai, Teva, Sanofi, Johnson & Johnson, Novartis, Roche, Eli Lilly and Pfizer, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Cancer Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Cancer Drugs.
The Cancer Drugs market size, estimations, and forecasts are provided in terms of sales volume (k tons) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Cancer Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.

Cancer Drugs Segment by Company

Takeda
Eisai
Teva
Sanofi
Johnson & Johnson
Novartis
Roche
Eli Lilly
Pfizer
Bayer
Amgen
AbbVie
AstraZeneca
Otsuka
Merck KGaA
Merck & Co.
Ipsen
Gilead Sciences
Celgene
Bristol-Myers Squibb
Biogen Idec
Astellas
Cancer Drugs Segment by Type

Targeted Therapy
Hormonal Therapy (Biologic Therapy)
Chemotherapy
Immunotherapy
Others
Cancer Drugs Segment by Application

Blood Cancer
Gastrointestinal Cancer
Breast Cancer
Prostate Cancer
Respiratory/Lung Cancer
Other Cancers
Cancer Drugs Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cancer Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Cancer Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cancer Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Cancer Drugs manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Sales, revenue of Cancer Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.
Chapter 13: Concluding Insights of the report.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

128 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Market Growth Prospects
1.2.1 Global Cancer Drugs Market Size Estimates and Forecasts (2020-2031)
1.2.2 Global Cancer Drugs Sales Estimates and Forecasts (2020-2031)
1.3 Cancer Drugs Market by Type
1.3.1 Targeted Therapy
1.3.2 Hormonal Therapy (Biologic Therapy)
1.3.3 Chemotherapy
1.3.4 Immunotherapy
1.3.5 Others
1.4 Global Cancer Drugs Market Size by Type
1.4.1 Global Cancer Drugs Market Size Overview by Type (2020-2031)
1.4.2 Global Cancer Drugs Historic Market Size Review by Type (2020-2025)
1.4.3 Global Cancer Drugs Forecasted Market Size by Type (2026-2031)
1.5 Key Regions Market Size by Type
1.5.1 North America Cancer Drugs Sales Breakdown by Type (2020-2025)
1.5.2 Europe Cancer Drugs Sales Breakdown by Type (2020-2025)
1.5.3 Asia-Pacific Cancer Drugs Sales Breakdown by Type (2020-2025)
1.5.4 South America Cancer Drugs Sales Breakdown by Type (2020-2025)
1.5.5 Middle East and Africa Cancer Drugs Sales Breakdown by Type (2020-2025)
2 Global Market Dynamics
2.1 Cancer Drugs Industry Trends
2.2 Cancer Drugs Industry Drivers
2.3 Cancer Drugs Industry Opportunities and Challenges
2.4 Cancer Drugs Industry Restraints
3 Market Competitive Landscape by Company
3.1 Global Top Players by Cancer Drugs Revenue (2020-2025)
3.2 Global Top Players by Cancer Drugs Sales (2020-2025)
3.3 Global Top Players by Cancer Drugs Price (2020-2025)
3.4 Global Cancer Drugs Industry Company Ranking, 2023 VS 2024 VS 2025
3.5 Global Cancer Drugs Major Company Production Sites & Headquarters
3.6 Global Cancer Drugs Company, Product Type & Application
3.7 Global Cancer Drugs Company Establishment Date
3.8 Market Competitive Analysis
3.8.1 Global Cancer Drugs Market CR5 and HHI
3.8.2 Global Top 5 and 10 Cancer Drugs Players Market Share by Revenue in 2024
3.8.3 2023 Cancer Drugs Tier 1, Tier 2, and Tier 3
4 Cancer Drugs Regional Status and Outlook
4.1 Global Cancer Drugs Market Size and CAGR by Region: 2020 VS 2024 VS 2031
4.2 Global Cancer Drugs Historic Market Size by Region
4.2.1 Global Cancer Drugs Sales in Volume by Region (2020-2025)
4.2.2 Global Cancer Drugs Sales in Value by Region (2020-2025)
4.2.3 Global Cancer Drugs Sales (Volume & Value), Price and Gross Margin (2020-2025)
4.3 Global Cancer Drugs Forecasted Market Size by Region
4.3.1 Global Cancer Drugs Sales in Volume by Region (2026-2031)
4.3.2 Global Cancer Drugs Sales in Value by Region (2026-2031)
4.3.3 Global Cancer Drugs Sales (Volume & Value), Price and Gross Margin (2026-2031)
5 Cancer Drugs by Application
5.1 Cancer Drugs Market by Application
5.1.1 Blood Cancer
5.1.2 Gastrointestinal Cancer
5.1.3 Breast Cancer
5.1.4 Prostate Cancer
5.1.5 Respiratory/Lung Cancer
5.1.6 Other Cancers
5.2 Global Cancer Drugs Market Size by Application
5.2.1 Global Cancer Drugs Market Size Overview by Application (2020-2031)
5.2.2 Global Cancer Drugs Historic Market Size Review by Application (2020-2025)
5.2.3 Global Cancer Drugs Forecasted Market Size by Application (2026-2031)
5.3 Key Regions Market Size by Application
5.3.1 North America Cancer Drugs Sales Breakdown by Application (2020-2025)
5.3.2 Europe Cancer Drugs Sales Breakdown by Application (2020-2025)
5.3.3 Asia-Pacific Cancer Drugs Sales Breakdown by Application (2020-2025)
5.3.4 South America Cancer Drugs Sales Breakdown by Application (2020-2025)
5.3.5 Middle East and Africa Cancer Drugs Sales Breakdown by Application (2020-2025)
6 Company Profiles
6.1 Takeda
6.1.1 Takeda Comapny Information
6.1.2 Takeda Business Overview
6.1.3 Takeda Cancer Drugs Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Takeda Cancer Drugs Product Portfolio
6.1.5 Takeda Recent Developments
6.2 Eisai
6.2.1 Eisai Comapny Information
6.2.2 Eisai Business Overview
6.2.3 Eisai Cancer Drugs Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Eisai Cancer Drugs Product Portfolio
6.2.5 Eisai Recent Developments
6.3 Teva
6.3.1 Teva Comapny Information
6.3.2 Teva Business Overview
6.3.3 Teva Cancer Drugs Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Teva Cancer Drugs Product Portfolio
6.3.5 Teva Recent Developments
6.4 Sanofi
6.4.1 Sanofi Comapny Information
6.4.2 Sanofi Business Overview
6.4.3 Sanofi Cancer Drugs Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Sanofi Cancer Drugs Product Portfolio
6.4.5 Sanofi Recent Developments
6.5 Johnson & Johnson
6.5.1 Johnson & Johnson Comapny Information
6.5.2 Johnson & Johnson Business Overview
6.5.3 Johnson & Johnson Cancer Drugs Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Johnson & Johnson Cancer Drugs Product Portfolio
6.5.5 Johnson & Johnson Recent Developments
6.6 Novartis
6.6.1 Novartis Comapny Information
6.6.2 Novartis Business Overview
6.6.3 Novartis Cancer Drugs Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Novartis Cancer Drugs Product Portfolio
6.6.5 Novartis Recent Developments
6.7 Roche
6.7.1 Roche Comapny Information
6.7.2 Roche Business Overview
6.7.3 Roche Cancer Drugs Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Roche Cancer Drugs Product Portfolio
6.7.5 Roche Recent Developments
6.8 Eli Lilly
6.8.1 Eli Lilly Comapny Information
6.8.2 Eli Lilly Business Overview
6.8.3 Eli Lilly Cancer Drugs Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Eli Lilly Cancer Drugs Product Portfolio
6.8.5 Eli Lilly Recent Developments
6.9 Pfizer
6.9.1 Pfizer Comapny Information
6.9.2 Pfizer Business Overview
6.9.3 Pfizer Cancer Drugs Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Pfizer Cancer Drugs Product Portfolio
6.9.5 Pfizer Recent Developments
6.10 Bayer
6.10.1 Bayer Comapny Information
6.10.2 Bayer Business Overview
6.10.3 Bayer Cancer Drugs Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Bayer Cancer Drugs Product Portfolio
6.10.5 Bayer Recent Developments
6.11 Amgen
6.11.1 Amgen Comapny Information
6.11.2 Amgen Business Overview
6.11.3 Amgen Cancer Drugs Sales, Revenue and Gross Margin (2020-2025)
6.11.4 Amgen Cancer Drugs Product Portfolio
6.11.5 Amgen Recent Developments
6.12 AbbVie
6.12.1 AbbVie Comapny Information
6.12.2 AbbVie Business Overview
6.12.3 AbbVie Cancer Drugs Sales, Revenue and Gross Margin (2020-2025)
6.12.4 AbbVie Cancer Drugs Product Portfolio
6.12.5 AbbVie Recent Developments
6.13 AstraZeneca
6.13.1 AstraZeneca Comapny Information
6.13.2 AstraZeneca Business Overview
6.13.3 AstraZeneca Cancer Drugs Sales, Revenue and Gross Margin (2020-2025)
6.13.4 AstraZeneca Cancer Drugs Product Portfolio
6.13.5 AstraZeneca Recent Developments
6.14 Otsuka
6.14.1 Otsuka Comapny Information
6.14.2 Otsuka Business Overview
6.14.3 Otsuka Cancer Drugs Sales, Revenue and Gross Margin (2020-2025)
6.14.4 Otsuka Cancer Drugs Product Portfolio
6.14.5 Otsuka Recent Developments
6.15 Merck KGaA
6.15.1 Merck KGaA Comapny Information
6.15.2 Merck KGaA Business Overview
6.15.3 Merck KGaA Cancer Drugs Sales, Revenue and Gross Margin (2020-2025)
6.15.4 Merck KGaA Cancer Drugs Product Portfolio
6.15.5 Merck KGaA Recent Developments
6.16 Merck & Co.
6.16.1 Merck & Co. Comapny Information
6.16.2 Merck & Co. Business Overview
6.16.3 Merck & Co. Cancer Drugs Sales, Revenue and Gross Margin (2020-2025)
6.16.4 Merck & Co. Cancer Drugs Product Portfolio
6.16.5 Merck & Co. Recent Developments
6.17 Ipsen
6.17.1 Ipsen Comapny Information
6.17.2 Ipsen Business Overview
6.17.3 Ipsen Cancer Drugs Sales, Revenue and Gross Margin (2020-2025)
6.17.4 Ipsen Cancer Drugs Product Portfolio
6.17.5 Ipsen Recent Developments
6.18 Gilead Sciences
6.18.1 Gilead Sciences Comapny Information
6.18.2 Gilead Sciences Business Overview
6.18.3 Gilead Sciences Cancer Drugs Sales, Revenue and Gross Margin (2020-2025)
6.18.4 Gilead Sciences Cancer Drugs Product Portfolio
6.18.5 Gilead Sciences Recent Developments
6.19 Celgene
6.19.1 Celgene Comapny Information
6.19.2 Celgene Business Overview
6.19.3 Celgene Cancer Drugs Sales, Revenue and Gross Margin (2020-2025)
6.19.4 Celgene Cancer Drugs Product Portfolio
6.19.5 Celgene Recent Developments
6.20 Bristol-Myers Squibb
6.20.1 Bristol-Myers Squibb Comapny Information
6.20.2 Bristol-Myers Squibb Business Overview
6.20.3 Bristol-Myers Squibb Cancer Drugs Sales, Revenue and Gross Margin (2020-2025)
6.20.4 Bristol-Myers Squibb Cancer Drugs Product Portfolio
6.20.5 Bristol-Myers Squibb Recent Developments
6.21 Biogen Idec
6.21.1 Biogen Idec Comapny Information
6.21.2 Biogen Idec Business Overview
6.21.3 Biogen Idec Cancer Drugs Sales, Revenue and Gross Margin (2020-2025)
6.21.4 Biogen Idec Cancer Drugs Product Portfolio
6.21.5 Biogen Idec Recent Developments
6.22 Astellas
6.22.1 Astellas Comapny Information
6.22.2 Astellas Business Overview
6.22.3 Astellas Cancer Drugs Sales, Revenue and Gross Margin (2020-2025)
6.22.4 Astellas Cancer Drugs Product Portfolio
6.22.5 Astellas Recent Developments
7 North America by Country
7.1 North America Cancer Drugs Sales by Country
7.1.1 North America Cancer Drugs Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
7.1.2 North America Cancer Drugs Sales by Country (2020-2025)
7.1.3 North America Cancer Drugs Sales Forecast by Country (2026-2031)
7.2 North America Cancer Drugs Market Size by Country
7.2.1 North America Cancer Drugs Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
7.2.2 North America Cancer Drugs Market Size by Country (2020-2025)
7.2.3 North America Cancer Drugs Market Size Forecast by Country (2026-2031)
8 Europe by Country
8.1 Europe Cancer Drugs Sales by Country
8.1.1 Europe Cancer Drugs Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
8.1.2 Europe Cancer Drugs Sales by Country (2020-2025)
8.1.3 Europe Cancer Drugs Sales Forecast by Country (2026-2031)
8.2 Europe Cancer Drugs Market Size by Country
8.2.1 Europe Cancer Drugs Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
8.2.2 Europe Cancer Drugs Market Size by Country (2020-2025)
8.2.3 Europe Cancer Drugs Market Size Forecast by Country (2026-2031)
9 Asia-Pacific by Country
9.1 Asia-Pacific Cancer Drugs Sales by Country
9.1.1 Asia-Pacific Cancer Drugs Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
9.1.2 Asia-Pacific Cancer Drugs Sales by Country (2020-2025)
9.1.3 Asia-Pacific Cancer Drugs Sales Forecast by Country (2026-2031)
9.2 Asia-Pacific Cancer Drugs Market Size by Country
9.2.1 Asia-Pacific Cancer Drugs Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
9.2.2 Asia-Pacific Cancer Drugs Market Size by Country (2020-2025)
9.2.3 Asia-Pacific Cancer Drugs Market Size Forecast by Country (2026-2031)
10 South America by Country
10.1 South America Cancer Drugs Sales by Country
10.1.1 South America Cancer Drugs Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
10.1.2 South America Cancer Drugs Sales by Country (2020-2025)
10.1.3 South America Cancer Drugs Sales Forecast by Country (2026-2031)
10.2 South America Cancer Drugs Market Size by Country
10.2.1 South America Cancer Drugs Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
10.2.2 South America Cancer Drugs Market Size by Country (2020-2025)
10.2.3 South America Cancer Drugs Market Size Forecast by Country (2026-2031)
11 Middle East and Africa by Country
11.1 Middle East and Africa Cancer Drugs Sales by Country
11.1.1 Middle East and Africa Cancer Drugs Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
11.1.2 Middle East and Africa Cancer Drugs Sales by Country (2020-2025)
11.1.3 Middle East and Africa Cancer Drugs Sales Forecast by Country (2026-2031)
11.2 Middle East and Africa Cancer Drugs Market Size by Country
11.2.1 Middle East and Africa Cancer Drugs Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
11.2.2 Middle East and Africa Cancer Drugs Market Size by Country (2020-2025)
11.2.3 Middle East and Africa Cancer Drugs Market Size Forecast by Country (2026-2031)
12 Value Chain and Sales Channels Analysis
12.1 Cancer Drugs Value Chain Analysis
12.1.1 Cancer Drugs Key Raw Materials
12.1.2 Key Raw Materials Price
12.1.3 Raw Materials Key Suppliers
12.1.4 Manufacturing Cost Structure
12.1.5 Cancer Drugs Production Mode & Process
12.2 Cancer Drugs Sales Channels Analysis
12.2.1 Direct Comparison with Distribution Share
12.2.2 Cancer Drugs Distributors
12.2.3 Cancer Drugs Customers
13 Concluding Insights
14 Appendix
14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
14.6 Disclaimer
How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.